Physician

Paul Eric Szwejbka, M.D., M.P.H.

According to 2025 Medicare claims, Paul Szwejbka, M.D., M.P.H. (NPI: 1366447757) practices neurology in the Fayetteville, NC market, with the plurality of this provider's patient population coming from Cumberland, NC. This provider's primary affiliated billing organization is CUMBERLAND NEUROLOGY, P.A. (NPI: 1467581512) and primary practice location at 28314-2567.

Szwejbka's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 295 traditional Medicare patients, billed 19,171 HCPCS/CPT codes, and received $543,828 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,970 prescription claims across 205 beneficiaries totaling $1,466,686 in drug costs, led by Hizentra (Immun Glob G(Igg)/Pro/Iga 0-50). 2019 DME data shows 20 claims. Open Payments data shows 59 records totaling $1,632. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $850,060 to $1,466,686. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	457	10,092	$181,096
2016	375	9,114	$184,559
2017	432	23,087	$480,535
2018	517	35,384	$795,845
2019	500	31,549	$757,648
2020	342	25,972	$702,242
2021	323	24,939	$771,754
2022	314	25,918	$703,098
2023	312	21,502	$649,382
2024	295	19,171	$543,828

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	168	1,813	$850,060
2016	147	1,565	$982,600
2017	163	1,594	$1,000,534
2018	213	1,838	$1,064,092
2019	223	2,133	$2,148,908
2020	190	1,973	$2,456,941
2021	178	1,958	$1,986,562
2022	201	1,977	$1,547,124
2023	201	1,980	$1,865,975
2024	205	1,970	$1,466,686

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	20	$171
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	46	46	$144
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	147	242	$115
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	210	323	$80
95886	Needle measurement of electrical activity in arm or leg muscles, complete study	83	194	$70
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	227	435	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Hizentra	Immun Glob G(Igg)/Pro/Iga 0-50	22	616	$325,022
Privigen	Immun Glob G(Igg)/Pro/Iga 0-50	12	336	$199,531
Rebif Rebidose	Interferon Beta-1a/Albumin	11	308	$113,266
Lamictal Xr	Lamotrigine	15	570	$58,122
Nuplazid	Pimavanserin Tartrate	11	330	$53,846

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	59	$1,632	TG Therapeutics, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Paul Eric Szwejbka, M.D., M.P.H.?

Tedicare shows public-source Medicare data for Paul Eric Szwejbka, M.D., M.P.H. (NPI 1366447757), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Paul Eric Szwejbka, M.D., M.P.H. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Paul Eric Szwejbka, M.D., M.P.H.?

Paul Eric Szwejbka, M.D., M.P.H. is linked to CUMBERLAND NEUROLOGY, P.A. (billing NPI 1467581512) in the available physician profile data.

Does Paul Eric Szwejbka, M.D., M.P.H. have Open Payments data?

Paul Eric Szwejbka, M.D., M.P.H. has 59 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.